I am no stats professor but I believe the DMX200 vs placebo reduction should be 2%, not 12%. This is the problematic area - the part where the legacy effect argument lies.
I thought the average 14% reduction for DMX200 vs baseline is very close to statistical significance (15%) but this is not observed in DMX200 vs placebo. I saw a post where one postulates that it is easy to plot this out and conclude whether there is any legacy effect or not - I don't think it is that simple and straightforward - Even if the graph visually tells you there is a correlation, it is not necessarily a legacy effect (cause) from DMX 200. I believe they will need to review medication, diet, etc.. before jumping to a conclusion. So, I thought they are being careful not to mislead the market unless they are fairly certain (not just by looking at numbers alone).
- Forums
- ASX - By Stock
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
I am no stats professor but I believe the DMX200 vs placebo...
-
- There are more pages in this discussion • 284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
56.0¢ |
Change
0.035(6.67%) |
Mkt cap ! $308.1M |
Open | High | Low | Value | Volume |
51.5¢ | 57.3¢ | 50.5¢ | $2.179M | 3.991M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 30558 | 56.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.5¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 30558 | 0.560 |
3 | 25521 | 0.555 |
7 | 539331 | 0.550 |
3 | 15269 | 0.545 |
2 | 7430 | 0.540 |
Price($) | Vol. | No. |
---|---|---|
0.565 | 10000 | 1 |
0.570 | 73781 | 4 |
0.575 | 47975 | 3 |
0.580 | 122045 | 5 |
0.585 | 107509 | 5 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |